Works Cited

Animal-Related Health Risks

Course #94924 - $90 -

  • Back to Course Home
  • Participation Instructions
    • Review the course material online or in print.
    • Complete the course evaluation.
    • Review your Transcript to view and print your Certificate of Completion. Your date of completion will be the date (Pacific Time) the course was electronically submitted for credit, with no exceptions. Partial credit is not available.

1. Blancou J, Meslin FX. Brief review of the history of zoonoses. Rev Sci Tech. 2000;19(1):15-22.

2. Uppsala Universitet. Systema Naturae – An Epoch-Making Book. Available at https://www.botan.uu.se/learning/linnaeus-online/plants-and-animals/the-order-in-nature/systema-naturae-an-epoch-making-book. Last accessed April 25, 2023.

3. Berger D. A brief history of medical diagnosis and the birth of the clinical laboratory. Part 1: ancient times through the 19th century. MLO Med Lab Obs. 1999;31(7):28-30, 32, 34-40.

4. Medicine Net. Medical Definition of Koch's Postulates. Available at https://www.medicinenet.com/kochs_postulates/definition.htm. Last accessed April 25, 2023.

5. Berger D. A brief history of medical diagnosis and the birth of the clinical laboratory. Part 2: laboratory science and professional certification in the 20th century. MLO Med Lab Obs. 1999;31(8):32-34, 36, 38.

6. Centers for Disease Control and Prevention. Eastern equine encephalitis—Florida, eastern United States, 1991. MMWR. 1991;40(31):533-535.

7. Burroughs T, Knobler S, Lederberg J (eds). The Emergence of Zoonotic Diseases: Understanding the Impact on Animal and Human Health. Washington, DC: National Academy Press; 2002.

8. Gilbert AT, Petersen BW, Recuenco S, et al. Evidence of rabies virus exposure among humans in the Peruvian Amazon. Am J Trop Med Hyg . 2012;87(2):206-215.

9. Sanchez A, Ksiazek TG, Rollin PE, et al. Reemergence of Ebola virus in Africa. Emerg Infect Dis. 1995;1(3):96-97.

10. Centers for Disease Control and Prevention. About Parasites. Available athttps://www.cdc.gov/parasites/about.html. Last accessed April 25, 2023.

11. Horton HH, Misrahi JJ, Matthews GW, Kocher PL. Critical biological agents: disease reporting as a tool for determining bioterrorism preparedness. J Law Med Ethics. 2002;30(2):262-266.

12. 12. Heymann DL (ed). Control of Communicable Diseases Manual. 21st ed. Washington, DC: World Health Organization/American Public Health Association; 2022.

13. Centers for Disease Control and Prevention. Laboratory Identification of Parasitic Diseases of Public Health Concern: Taeniasis. Available athttps://www.cdc.gov/dpdx/taeniasis/index.html. Last accessed April 25, 2023.

14. Hugh-Jones ME, Hubbert WT, Hagstad HV. Zoonoses: Recognition, Control and Prevention. Ames, IA: University of Iowa Press; 1995.

15. Huff JL, Eberle R, Capitanio J, Zhou SS, Barry PA. Differential detection of B virus and rhesus cytomegalovirus in rhesus macaques. J Gen Virol. 2003;84(Pt 1):83-92.

16. National Institute of Allergy and Infectious Diseases. Lyme Disease. Available athttps://www.niaid.nih.gov/diseases-conditions/lyme-disease. Last accessed April 25, 2023.

17. Schwartz AM, Hinckley AF, Mead PS, et al. Surveillance for Lyme disease – United States, 2008-2015. MMWR. 2017;66(22):1-12.

18. 18. Centers for Disease Control and Prevention. Lyme Disease: Data and Surveillance. Available at https://www.cdc.gov/lyme/datasurveillance/index.html. Last accessed April 25, 2023.

19. Association of Public Health Laboratories. Suggested Reporting Language, Interpretation and Guidance Regarding Lyme Disease Serologic Test Results. Available at https://www.aphl.org/aboutAPHL/publications/Documents/ID-2021-Lyme-Disease-Serologic-Testing-Reporting.pdf. Last accessed April 25, 2023.

20. Grier T. Will There Ever Be An Accurate Test for Lyme Disease? Available athttps://owndoc.com/pdf/when-accurate-lyme-tests.pdf. Last accessed April 25, 2023.

21. Lin T, Oliver JH Jr, Gao L, Kollars TM Jr, Clark KL. Genetic heterogeneity of Borrelia burgdorferi sensu lato in the southern United States based on restriction fragment length polymorphism and sequence analysis. J Clin Microbiol. 2001;39(7):2500-2507.

22. Centers for Disease Control and Prevention. [Archived Content]. New Lyme-Disease-Causing Bacteria Species Discovered. Available athttps://www.cdc.gov/media/releases/2016/p0208-lyme-disease.html. Last accessed April 25, 2023.

23. Humane Society of the United States. Lyme Disease. Available athttps://www.humanesociety.org/resources/lyme-disease. Last accessed April 25, 2023.

24. Godin AJ. Wild Mammals of New England. Baltimore, MD: Johns Hopkins University Press; 1977.

25. Steere AC. A 58-year old man with a diagnosis of chronic Lyme disease. JAMA. 2002;288(8):1002-1010.

26. Spielman A. Host Abundance and Transmission of Ixodes-Borne Zoonoses. Cambridge, MA: Harvard University Press; 1994.

27. Steere AC, Coburn J, Glickstein L. The emergence of Lyme disease. J Clin Invest. 2004;113(8):1093-1101.

28. Depietropaolo DL, Powers JH, Gill JM. Diagnosis of Lyme disease. Am Fam Physician. 2005;72(2):297-304.

29. Halperin JJ, Shapiro ED, Logigian E, et al. Practice parameter: treatment of nervous system Lyme disease (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology.Neurology. 2007;69(1):91-102.

30. Steere AC, McHugh G, Suarez C, Hoitt J, Damle N, Sikland VK. Prospective study of coinfection in patients with erythema migrans. Clin Infect Dis. 2003;36(8):1078-1081.

31. Centers for Disease Control and Prevention. Ehrlichiosis. Available athttps://www.cdc.gov/ehrlichiosis. Last accessed April 25, 2023.

32. Telford SR 3rd, Pollack RJ, Spielman A. Emerging vector-borne infections. Infect Dis Clin North Am. 1991;5(1):7-17.

33. Dattwyler RJ, Volkman DJ, Luft BJ, Halperin JJ, Thomas J, Golightly MG. Seronegative Lyme disease: dissociation of specific T- and B-lymphocyte responses to Borrelia burgdorferi. N Engl J Med. 1988;319(22):1441-1446.

34. Centers for Disease Control and Prevention. Laboratory Tests and Practices That Are Not Currently Recommended. Available at https://www.cdc.gov/lyme/diagnosistesting/labtest/otherlab/index.html. Last accessed April 25, 2023.

35. Centers for Disease Control and Prevention. Lyme Disease: Diagnosis and Testing. Available at https://www.cdc.gov/lyme/diagnosistesting/index.html. Last accessed April 25, 2023.

36. Mead P, Petersen J, Hinckley A. Updated CDC recommendation for serologic diagnosis of Lyme disease. MMWR. 2019;68(32):703.

37. 37. U.S. Food and Drug Administration. FDA News Release: FDA Clears New Indications for Existing Lyme Disease Tests That May Help Streamline Diagnoses. Available at https://www.fda.gov/news-events/press-announcements/fda-clears-new-indications-existing-lyme-disease-tests-may-help-streamline-diagnoses. Last accessed April 25, 2023.

38. IgeneX, Inc. Reference Laboratory Manual. Palo Alto, CA: IgeneX, Inc.; 1998: 1-17.

39. Centers for Disease Control and Prevention. Notice to readers: recommendations for test performance and interpretation from the second national conference on serologic diagnosis of Lyme disease. MMWR. 1995;44(31):590-591.

40. Centers for Disease Control and Prevention. Notice to readers: caution regarding testing for Lyme disease. MMWR. 2005;54(5):125.

41. Meyerhoff JO. Lyme Disease. Available athttps://emedicine.medscape.com/article/330178-overview. Last accessed April 25, 2023.

42. Cameron DJ, Johnson LB, Maloney EL. Evidence assessments and guideline recommendations in Lyme disease: the clinical management of known tick bites, erythema migrans rashes and persistent disease. Expert Rev Anti Infect Ther. 2014;12(9):1103-1135.

43. 43. Wormser GP, Dattwyler RJ, Shapiro ED, et al. The clinical assessment, treatment, and prevention of Lyme disease, human granulocytic anaplasmosis, and babesiosis: clinical practice guidelines by the Infectious Diseases Society of America. Clin Infect Dis. 2006;43(9):1089-1134.

44. Centers for Disease Control and Prevention. West Nile Virus. Available athttps://www.cdc.gov/westnile/index.html. Last accessed April 25, 2023.

45. Centers for Disease Control and Prevention. Lyme Disease Vaccine. Available athttps://www.cdc.gov/lyme/prev/vaccine.html. Last accessed April 25, 2023.

46. Dennis DT, Inglesby TV, Henderson DA, et al. Tularemia as a biological weapon: medical and public health management. JAMA. 2001;285(21):2763-2773.

47. Centers for Disease Control and Prevention. Key Facts about Tularemia. Available athttps://emergency.cdc.gov/agent/tularemia/ facts.asp. Last accessed April 25, 2023.

48. Bratton RL, Corey R. Tick-borne disease. Am Fam Physician. 2005;71(12):2323-2330.

49. Cleveland KO. Tularemia. Available athttps://emedicine.medscape.com/article/230923-overview. Last accessed April 25, 2023.

50. 50. Merck Manual. Tularemia. Available at https://www.merckmanuals.com/professional/infectious-diseases/gram-negative-bacilli/tularemia#v26500089. Last accessed April 25, 2023.

51. New York State Department of Health. Tularemia. Available athttps://www.health.ny.gov/diseases/communicable/tularemia/fact_sheet.htm. Last accessed April 25, 2023.

52. Centers for Disease Control and Prevention. Tularemia associated with a hamster bite—Colorado, 2004. MMWR. 2005;53(51):1202-1203.

53. Yuen JC, Malotky MV. Francisella tularensis osteomyelitis of the hand following a cat bite: a case of clinical suspicion. Plast Reconstr Surg. 2011;128(1):37e-39e.

54. Weinstein RA, Singh K. Laboratory-acquired infections. Clin Infect Dis. 2009;49(1):142-147.

55. LexiComp Online. Available at https://online.lexi.com/lco/action/login. Last accessed April 25, 2023.

56. Reed DS, Smith LP, Cole KS, Santiago AE, Mann BJ, Barry EM. Live attenuated mutants of Francisella tularensis protect rabbits against aerosol challenge with a virulent type A strain. Am Soc Microbiol. 2014;82(5):2098-2105.

57. Centers for Disease Control and Prevention. Tularemia: Prevention. Available athttps://www.cdc.gov/tularemia/prevention. Last accessed April 25, 2023.

58. Centers for Disease Control and Prevention. Rocky Mountain Spotted Fever (RMSF). Available at https://www.cdc.gov/rmsf/index.html. Last accessed April 25, 2023.

59. Demma LJ, Traeger MS, Nicholson WL, et al. Rocky Mountain spotted fever from an unexpected tick vector in Arizona. N Engl J Med. 2005;353(6):587-594.

60. Rasmussen SA, Kent CK, Casey CG, et al. Diagnosis and management of tickborne rickettsial diseases: Rocky Mountain Spotted Fever and other spotted fever group rickettsioses, ehrlichioses, and anaplasmosis – United States. MMWR;65(2):1-44.

61. Pritt BS, Sloan LM, Hoang DK, et al. Emergence of a new pathogenic Ehrlichia species, Wisconsin and Minnesota, 2009. N Engl J Med. 2011;365(5):422-429.

62. New York State Department of Health. Anaplasmosis and Ehrlichiosis: Tick-Borne Bacterial Infections. Available athttps:// www.health.ny.gov/diseases/communicable/ehrlichiosis/fact_sheet.htm. Last accessed April 25, 2023.

63. 63. Centers for Disease Control and Prevention. Ehrlichiosis. For Healthcare Providers. Available at https://www.cdc.gov/ehrlichiosis/healthcare-providers/index.html. Last accessed April 25, 2023.

64. Romer Y, Adcock K, Wei Z, et al. Isolation of Heartland virus from lone star ticks, Georgia, USA, 2019. Emerg Infect Dis. 2022;28(4):786-792.

65. Pastula DM, Turabelidze G, Yates KF. Notes from the field: Heartland virus disease—United States, 2012–2013. MMWR. 2014;63(12):270-271.

66. Centers for Disease Control and Prevention. Parasites: Babesiosis: Resources for Health Professionals. Available athttps://www.cdc.gov/parasites/babesiosis/health_professionals/index.htmlLast accessed April 25, 2023.

67. Western KA, Benson GD, Gleason NN, Healy GR, Schultz MG. Babesiosis in a Massachusetts resident. N Engl J Med. 1970;283(16):854-856.

68. Centers for Disease Control and Prevention. Travelers' Health. CDC Yellow Book 2020. Available at https://wwwnc.cdc.gov/travel/page/yellowbook-home-2020. Last accessed April 25, 2023.

69. Petersen LR, Marfin AA, Gubler DJ. West Nile virus. JAMA. 2003;290(4):524-528.

70. Centers for Disease Control and Prevention. West Nile Virus: Final Annual Maps and Data for 1999–2021. Available athttps://www.cdc.gov/westnile/statsmaps/finalmapsdata/index.html. Last accessed April 25, 2023.

71. Government of Canada. Surveillance of West Nile Virus. Available at https://www.canada.ca/en/public-health/services/diseases/west-nile-virus/surveillance-west-nile-virus.html. Last accessed April 25, 2023.

72. Scherret JH, Poidinger M, Mackenzie JS, et al. The relationships between West Nile and Kunjin viruses. Emerg Infect Dis. 2001;7(4):697-705.

73. Centers for Disease Control and Prevention. West Nile virus activity: Eastern United States, 2001. MMWR. 2001;50(29):617-619.

74. Campbell GL, Marfin AA, Lanciotti RS, Gubler DJ. West Nile virus. Lancet Infect Dis. 2002;2(9):519-529.

75. Klenk K, Snow J, Morgan K, et al. Alligators as West Nile virus amplifiers. Emerg Infect Dis. 2004;10(12):2150-2155.

76. Centers for Disease Control and Prevention. Update: West Nile virus activity—Northeastern United States, 2000. MMWR. 2000;49(36):820-822.

77. Petersen LR, Marfin AA. West Nile virus: a primer for the clinician. Ann Intern Med. 2002;137(3):173-179.

78. Sejvar JJ, Haddad MB, Tierney BC, et al. Neurologic manifestations and outcome of West Nile virus infection. JAMA. 2003;290(4): 511-515.

79. Hayes EB, Sejvar JJ, Zaki SR, Lanciotti RS, Bode AV, Campbell GL. Virology, pathology, and clinical manifestations of West Nile virus disease. Emerg Infect Dis. 2005;11(8):1174-1179.

80. Centers for Disease Control and Prevention. West Nile Virus in the United States: Guidelines for Surveillance, Prevention, and Control. Available athttps://www.cdc.gov/westnile/resources/pdfs/wnvGuidelines.pdf. Last accessed April 25, 2023.

81. 81. Salinas JD Jr. West Nile Virus. Available athttps://emedicine.medscape.com/article/312210-overview. Last accessed April 25, 2023.

82. Centers for Disease Control and Prevention. West Nile Virus. Treatment and Prevention. Available at https://www.cdc.gov/westnile/healthcareproviders/healthCareProviders-TreatmentPrevention.html. Last accessed April 25, 2023.

83. National Institutes for Health. NIH-Funded Vaccine for West Nile Virus Enters Human Clinical Trials. Available athttps://www.nih.gov/news-events/news-releases/nih-funded-vaccine-west-nile-virus-enters-human-clinical-trials. Last accessed April 25, 2023.

84. ClinicalTrials.gov. Phase 1 Trial of Inactivated West Nile Virus Vaccine. Available athttps://clinicaltrials.gov/ct2/show/NCT02337868. Last accessed April 25, 2023.

85. Hayes EB. Zika virus outside Africa. Emerg Infect Dis. 2009;15(9):1347-1350.

86. Fauci AS, Morens DM. Zika virus in the Americas: yet another arbovirus threat. N Engl J Med. 2016;374(7):601-604.

87. Centers for Disease Control and Prevention. Zika Cases in the United States. Available at https://www.cdc.gov/zika/reporting/index.html. Last accessed April 25, 2023.

88. Monaghan AJ, Morin CW, Steinhoff DF, et al. On the seasonal occurrence and abundance of the Zika virus vector mosquito Aedes aegypti in the contiguous United States. PLoS Curr. 2016;1.

89. Hills SL, Russell K, Hennessey M, et al. Transmission of Zika virus through sexual contact with travelers to areas of ongoing transmission—continental United States, 2016. MMWR. 2016;65(8):215-216.

90. European Centre for Disease Prevention and Control. Rapid Risk Assessment: Zika Virus Epidemic: Potential Association with Microcephaly and Guillain-Barré Syndrome, Second Update. Available athttps://www.ecdc.europa.eu/en/publications-data/rapid-risk-assessment-zika-virus-disease-epidemic-potential-association-0. Last accessed April 25, 2023.

91. U.S. Food and Drug Administration. FDA Advises Testing for Zika Virus in All Donated Blood and Blood Components in the US. Available athttps://www.fda.gov/news-events/press-announcements/fda-advises-testing-zika-virus-all-donated-blood-and-blood-components-us. Last accessed April 25, 2023.

92. Oster AM, Russell K, Stryker JE, et al. Update: interim guidance for prevention of sexual transmission of Zika virus—United States, 2016. MMWR. 2016;65(12):323-325.

93. Russell PK. The Zika pandemic: a perfect storm. PLoS Negl Trop Dis. 2016;10(3):e0004589.

94. Petersen LR, Jamieson DJ, Powers AM, Honein MA. Zika virus. N Engl J Med. 2016;374(16):1552-1563.

95. Brasil P, Pereira JP Jr, Raja Gabaglia C, et al. Zika virus infection in pregnant women in Rio de Janeiro: preliminary report. Obstet Gynecol Surv. 2016;71(6):331-333.

96. Carteaux G, Maquart M, Bedet A, et al. Zika virus associated with meningoencephalitis. N Engl J Med. 2016;374(16):1595-1596.

97. Karimi O, Goorhuis A, Schinkel J, et al. Thrombocytopenia and subcutaneous bleedings in a patient with Zika virus infection. Lancet. 2016;387(10022):939-940.

98. Hennessey M, Fischer M, Staples JE. Zika virus spreads to new areas: region of the Americas, May 2015–January 2016. MMWR. 2016;65(3):55-58.

99. Centers for Disease Control and Prevention. Testing for Zika Virus Infections. Available athttps://www.cdc.gov/zika/laboratories/types-of-tests.html. Last accessed April 25, 2023.

100. 100. U.S. Food and Drug Administration. Emergency Use Authorizations for Medical Devices. Zika Virus Emergency Use Authorization. Available at https://www.fda.gov/medical-devices/emergency-situations-medical-devices/emergency-use-authorizations-medical-devices#zika. Last accessed April 25, 2023.

101. Rabe IB, Staples JE, Villanueva J, et al. Interim guidance for interpretation of Zika virus antibody test results. MMWR. 2016;65(21):543-546.

102. Oduyebo T, Igbinosa I, Petersen EE, et al. Update: interim guidance for health care providers caring for pregnant women with possible Zika virus exposure—United States (Including U.S. Territories), July 2017. MMWR. 2017;66(29):781-793.

103. World Health Organization. Dengue and Severe Dengue. Available athttps://www.who.int/en/news-room/fact-sheets/detail/dengue-and-severe-dengue. Last accessed April 25, 2023.

104. Centers for Disease Control and Prevention. Dengue: For Healthcare Providers. Available at https://www.cdc.gov/dengue/healthcare-providers/index.html. Last accessed April 25, 2023.

105. Centers for Disease Control and Prevention. Dengue: Statistics and Maps. Available athttps://www.cdc.gov/dengue/statistics-maps/index.html. Last accessed April 25, 2023.

106. Centers for Disease Control and Prevention. Dengue. Available athttps://www.cdc.gov/dengue. Last accessed April 25, 2023.

107. Centers for Disease Control and Prevention. Dengue: Symptoms and Treatment. Available athttps://www.cdc.gov/dengue/symptoms. Last accessed April 25, 2023.

108. 108. U.S. Department of Health and Human Services. Centers for Disease Control and Prevention. Dengue and Dengue Hemorrhagic Fever. Available at https://www.cdc.gov/dengue/resources/denguedhf-information-for-health-care-practitioners_2009.pdf. Last accessed April 25, 2023.

109. U.S. Food and Drug Administration. FDA News Release. First FDA-Approved Vaccine for the Prevention of Dengue Disease in Endemic Regions. Available athttps://www.fda.gov/news-events/press-announcements/first-fda-approved-vaccine-prevention-dengue-disease-endemic-regions. Last accessed April 25, 2023.

110. Kirkpatrick BD, Whitehead SS, Pierce KK. The live attenuated dengue vaccine TV003 elicits complete protection against dengue in human challenge model. Sci Transl Med. 2016;8(330):330.

111. U.S. National Library of medicine. ClinicalTrials.gov. Available at https://clinicaltrials.gov/ct2/results?cond=Dengue&Search. Last accessed April 25, 2023.

112. Centers for Disease Control and Prevention. How is Rabies Transmitted? Available athttps://www.cdc.gov/rabies/transmission/index.html. Last accessed April 25, 2023.

113. Centers for Disease Control and Prevention. Rabies in the U.S. Available athttps://www.cdc.gov/rabies/location/usa/index.html. Last accessed April 25, 2023.

114. Monroe BP, Yager P, Blanton J, et al. Rabies surveillance in the United States during 2014. J Am Vet Med Assoc. 2016;248(7):777-788.

115. World Health Organization. Rabies. Available athttps://www.who.int/health-topics/rabies. Last accessed April 25, 2023.

116. 116. Ma X, Bonaparte S, Corbett P, et al. Rabies surveillance in the United States during 2021. J Am Vet Med Assoc. 2023;[Epub ahead of print].

117. Srinivasan A, Burton EC, Kuehnert MJ, et al. Transmission of rabies virus from an organ donor to four transplant recipients. N Engl J Med. 2005;352(11):1103-1111.

118. Wilde H, Briggs DJ, Meslin FX, Hemachttdha T, Sitprija V. Rabies update for travel medicine advisors. Clin Infect Dis. 2003;37(1):96-100.

119. Jackson AC, Warrell MJ, Rupprecht CE, et al. Management of rabies in humans. Clin Infect Dis. 2003;36(1):60-63.

120. Centers for Disease Control and Prevention. Human rabies prevention—United States, 2008. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR. 2008;57(RR03):1-26, 28.

121. 121. Centers for Disease Control and Prevention. Human death associated with bat rabies—California, 2003. MMWR. 2004;53(2): 33-35.

122. Centers for Disease Control and Prevention. How is Rabies Diagnosed? Available at https://www.cdc.gov/rabies/diagnosis/index.html. Last accessed April 25, 2023.

123. Centers for Disease Control and Prevention. Rabies Vaccine. Available athttps://www.cdc.gov/rabies/medical_care/vaccine.html. Last accessed April 25, 2023.

124. World Health Organization. WHO Guide for Rabies Pre- and Post-Exposure Prophylaxis in Humans. Available at https://apps.who.int/rabies/PEP_Prophylaxis_guideline_15_12_2014.pdf?ua=1 Last accessed April 25, 2023.

125. Rupprecht CE, Briggs D, Brown CM, et al. Use of a reduced (4-dose) vaccine schedule for postexposure prophylaxis to prevent human rabies: recommendations of the Advisory Committee on Immunization Practices. MMWR. 2010;59(RR2):1-9.

126. Medical College of Wisconsin. Pediatric Infectious Diseases. Welcome to the Rabies Registration Website. Available athttps://www.mcw.edu/departments/pediatrics/divisions/infectious-diseases/rabies-registry-website. Last accessed April 25, 2023.

127. Centers for Disease Control and Prevention. Recovery of a patient from clinical rabies—Wisconsin, 2004. MMWR. 2004;53(50):1171-1173.

128. 128. Centers for Disease Control and Prevention. Compendium of animal rabies prevention and control, 2005. MMWR. 2005;54(RR03): 1-8.

129. Centers for Disease Control and Prevention. Rabies Homepage. Prevention. Pre-Exposure Prophylaxis (PrEP). Available at https://www.cdc.gov/rabies/prevention/pre-exposure_vaccinations.html. Last accessed April 25, 2023.

130. World Health Organization. Rabies Vaccines: WHO Position Paper—April 2018. Available at https://www.who.int/publications/i/item/who-wer9316. Last accessed April 25, 2023.

131. Olsen CW. Influenza: pigs, people and public health. National Pork Board: Public Health Fact Sheet. 2004;2(6):1-3.

132. Centers for Disease Control and Prevention. Transmission of Avian Influenza A Viruses between Animals and People. Available athttps://www.cdc.gov/flu/avianflu/virus-transmission.htm. Last accessed April 25, 2023.

133. World Health Organization. Cumulative Number of Confirmed Human Cases for Avian Influenza A(H5N1) Reported to WHO, 2003–2023. Available at https://www.who.int/publications/m/item/cumulative-number-of-confirmed-human-cases-for-avian-influenza-a(h5n1)-reported-to-who-2003-2022-5-jan-2023. Last accessed April 25, 2023.

134. Centers for Disease Control and Prevention. First Human Avian Influenza A (H5N1) Virus Infection Reported in Americas. Available athttps://www.cdc.gov/flu/news/first-human-h5n1-americas.htm. Last accessed April 25, 2023.

135. World Health Organization. Avian Influenza: Assessing the Pandemic Threat. Available at https://apps.who.int/iris/bitstream/handle/10665/68985/WHO_CDS_2005.29.pdf. Last accessed April 25, 2023.

136. 136. Centers for Disease Control and Prevention. Public Health Threat of Highly Pathogenic Asian Avian Influenza A (H5N1) Virus. Available athttps://www.cdc.gov/flu/avianflu/h5n1-threat.htm. Last accessed April 25, 2023.

137. World Health Organization. Avian Influenza: 2006 - Indonesia. Available at https://www.who.int/emergencies/disease-outbreak-news/item/2006_05_22-en. Last accessed April 25, 2023.

138. Centers for Disease Control and Prevention. Avian Influenza in Birds. Available athttps://www.cdc.gov/flu/avianflu/avian-in-birds.htm. Last accessed April 25, 2023.

139. Hitt E. Avian Flu: What Clinicians Need to Know. Available athttps://www.medscape.com/viewarticle/468007. Last accessed April 25, 2023.

140. U.S. Department of Agriculture. USDA Avian Influenza Face Sheet. Available athttps://www.usda.gov/sites/default/files/documents/usda-avian-influenza-factsheet.pdf. Last accessed April 25, 2023.

141. World Health Organization. Influenza (Avian and Other Zoonotic). Available at https://www.who.int/news-room/fact-sheets/detail/influenza-(avian-and-other-zoonotic)? Last accessed April 25, 2023.

142. Li C, Hatta M, Nidom CA, et al. Reassortment between avian H5N1 and human H3N2 influenza viruses creates hybrid viruses with substantial virulence. Proc Natl Acad Sci U S A. 2010;107(10):4687-4692.

143. World Health Organization. Influenza A(H5N1) Highly Pathogenic Avian Influenza: Timeline of Major Events. Available at https://www.who.int/publications/m/item/influenza-a(h5n1)-highly-pathogenic-avian-influenza-timeline-of-major-events. Last accessed April 25, 2023.

144. Centers for Disease Control and Prevention. H5N1 Bird Flu: Current Situation Summary. Available athttps://www.cdc.gov/flu/avianflu/avian-flu-summary.htm. Last accessed April 25, 2023.

145. 145. Kayali G, Kandeil A, El-Shesheny R, et al. Avian influenza A(H5N1) virus in Egypt. Emerg Infect Dis. 2016;22(3).

146. Crispin SW, Cohen M, Mapes T. Bird-flu outbreak revives concerns stirred by SARS. Wall St J. January 28, 2004:A1.

147. National Institutes of Health. NIH Scientists Target Future Pandemic Strains of H5N1 Avian Influenza. Available athttps:// www.nih.gov/news-events/news-releases/nih-scientists-target-future-pandemic-strains-h5n1-avian-influenza. Last accessed April 25, 2023.

148. Gamblin SJ, Haire LF, Russell RJ, et al. The structure and receptor binding properties of the 1918 influenza hemagglutinin. Science. 2004;303(5665):1838-1842.

149. Centers for Disease Control and Prevention. Licensure of a high-dose inactivated influenza vaccine for persons aged ≥65 years (Fluzone high-dose) and guidance for use—United States, 2010. MMWR. 2010;59(16):485-486.

150. Centers for Disease Control and Prevention. [Archived Content]. Bird Infections with Highly-Pathogenic Avian Influenza A (H5N2), (H5N8), and (H5N1) Viruses: Recommendations for Human Health Investigations and Response. Available athttps://emergency.cdc.gov/han/han00378.asp. Last accessed April 25, 2023.

151. 151. Centers for Disease Control and Prevention. Influenza (Flu). Bird Flu Virus Infections in Humans. Available at https://www.cdc.gov/flu/avianflu/avian-in-humans.htm. Last accessed April 25, 2023.

152. Koopmans M, Wilbrink B, Conyn M, et al. Transmission of H7N7 avian influenza A virus to human beings during a large outbreak in commercial poultry farms in the Netherlands. Lancet. 2004;363(9409):587-593.

153. World Health Organization. WHO Rapid Advice Guidelines on Pharmacological Management of Humans Infected with Avian Influenza A (H5N1) Virus. Available athttps://apps.who.int/iris/bitstream/handle/10665/69373/WHO_PSM_PAR_2006.6_eng.pdf?sequence=1. Last accessed April 25, 2023.

154. Centers for Disease Control and Prevention. Avian Flu (Bird Flu). Available athttps://wwwnc.cdc.gov/travel/diseases/avian-bird-flu. Last accessed April 25, 2023.

155. Centers for Disease Control and Prevention. [Archived Content]. Interim Guidance for Airline Flight Crews and Persons Meeting Passengers Arriving from Areas with Avian Influenza (Updated). Available athttps://www.cdc.gov/h1n1flu/guidance/air-crew-dom-intl.htm. Last accessed April 25, 2023.

156. World Health Organization. Global Influenza Programme. Zoonotic Influenza Candidate Vaccine Viruses and Potency Testing Reagents. Influenza A (H5N1). Available at https://www.who.int/teams/global-influenza-programme/avian-influenza/vaccine-viruses/docs/default-source/influenza/cvvs/zoonotic-cvv/h5/summary_a_H5_cvv_nh2021_22_20210305. Last accessed April 25, 2023.

157. GlaxoKlineSmith. GlaxoSmithKline Receives New HHS Order for H5N1 Bulk Antigen; First Clinical Trials of Candidate Pre-Pandemic Flu Vaccine to Start. Available athttps://www.infectioncontroltoday.com/guidelines/glaxosmithkline-receives-new-hhs-order-h5n1-bulk-antigen-first-clinical-trials-candidate. Last accessed April 25, 2023.

158. Wong SS, Webby RJ. Traditional and new influenza vaccines.Clin Microbiol Rev. 2013;26(3):476-492.

159. 159. U.S. Food and Drug Administration. [Archived Content]. H5N1 Influenza Virus Vaccine, Manufactured by Sanofi Pasteur, Inc. Questions and Answers. Available at https://public4.pagefreezer.com/browse/FDA/06-02-2023T10:15/https://www.fda.gov/vaccines-blood-biologics/vaccines/h5n1-influenza-virus-vaccine-manufactured-sanofi-pasteur-inc-questions-and-answers. Last accessed April 25, 2023.

160. U.S. Food and Drug Administration. Influenza Virus Vaccine, H5N1 (for National Stockpile). Available at https://public4.pagefreezer.com/content/FDA/06-02-2023T10:15/https://www.fda.gov/vaccines-blood-biologics/vaccines/influenza-virus-vaccine-h5n1-national-stockpile. Last accessed April 25, 2023.

161. Science Daily. Universal Influenza Vaccine Tested Successfully in Humans. Available athttps://www.sciencedaily.com/releases/2008/01/080124185522.htm. Last accessed April 25, 2023.

162. World Health Organiztion. Zoonotic Influenza Candidate Vaccine Viruses and Potency Testing Reagents. Influenza A (H5N1). Summary of Status of Development and Available of A(H%N!) Candidate Vaccine Viruses and Potency Testing Reagents – Northern Hemisphere 2021-2022. Available at https://www.who.int/teams/global-influenza-programme/avian-influenza/vaccine-viruses/docs/default-source/influenza/cvvs/zoonotic-cvv/h5n1/summary_a_h5n1_cvv_nh2021_22_20210305. Last accessed April 25, 2023.

163. Centers for Disease Control and Prevention. Information on Swine/Variant Influenza Viruses. Available at https://www.cdc.gov/flu/swineflu. Last accessed April 25, 2023.

164. World Health Organization. Avian Influenza Update: Implications of H5N1 Infections in Pigs in China. 2004 - China. Available at https://www.who.int/emergencies/disease-outbreak-news/item/2004_08_25-en. Last accessed April 25, 2023.

165. World Health Organization. Pandemic (H1N1) 2010.. Available at https://www.who.int/emergencies/disease-outbreak-news/item/2010_07_30-en. Last accessed April 25, 2023.

166. Centers for Disease Control and Prevention. [Archived Content]. 2009 H1N1 Flu ("Swine Flu") and You. Available athttps://www.cdc.gov/h1n1flu/qa.htm. Last accessed April 25, 2023.

167. Centers for Disease Control and Prevention. [Archived Content]. Updated Interim Recommendations for the Use of Antiviral Medications in the Treatment and Prevention of Influenza for the 2009–2010 Season. Available athttps://www.cdc.gov/h1n1flu/recommendations.htm. Last accessed April 25, 2023.

168. World Health Organization. H1N1 in Post-Pandemic Period. Available at https://www.who.int/news/item/10-08-2010-h1n1-in-post-pandemic-period. Last accessed April 25, 2023.

169. 169. Centers for Disease Control and Prevention. 2009 H1N1 Pandemic Timeline. Available at https://www.cdc.gov/flu/pandemic-resources/2009-pandemic-timeline.html. Last accessed April 25, 2023.

170. Grohskopf LA, Blanton LH, Ferdinands JM, et al. Prevention and control of seasonal influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP) – United States, 2022-23 Influenza Season. MMWR. 2022;71(1):1-28.

171. Centers for Disease Control and Prevention. [Archived Content]. Interim Guidance on Infection Control Measures for 2009 H1N1 Influenza in Healthcare Settings, Including Protection of Healthcare Personnel. Available athttps://www.cdc.gov/h1n1flu/guidelines_infection_control.htm. Last accessed April 25, 2023.

172. California Department of Public Health. Variant Influenza Fact Sheet. Available athttps://www.cdph.ca.gov/Programs/CID/DCDC/CDPH%20Document%20Library/Immunization/VariantInfluenza-Quicksheet.pdf. Last accessed April 25, 2023.

173. Lau JTF, Griffiths S, Choi K-C, Lin C. Prevalence of preventive behaviors and associated factors during early phase of the H1N1 influenza epidemic. Am J Infect Control. 2010;38(5):374-380.

174. Fiore AE, Uyeki TM, Broder KM, et al. Prevention and control of influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2010. MMWR. 2010;59(RR8):1-62.

175. Centers for Disease Control and Prevention. Interim Guidance for Clinicians on Human Infections with Variant Influenza Viruses. Available at https://www.cdc.gov/flu/swineflu/interim-guidance-variant-flu.htm. Last accessed April 25, 2023.

176. 176. Centers for Disease Control and Prevention. Use of influenza A (H1N1) 2009 monovalent vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2009. MMWR. 2009;58(RR10):1-8.

177. Grohskopf LA, Sokolow LZ, Broder KR, et al. Prevention and control of seasonal influenza with vaccines. MMWR Recomm Rep. 2016;65(5):1-54.

178. Fiore AE, Shay DK, Broder K, et al. Prevention and control of influenza: recommendations of the Advisory Committee on Immunization Practices. MMWR. 2008;57(RR7):1-60.

179. Centers for Disease Control and Prevention. Influenza Antiviral Medications: Summary for Clinicians. Available at https://www.cdc.gov/flu/professionals/antivirals/summary-clinicians.htm#highrisk. Last accessed April 25, 2023.

180. U.S. Food and Drug Administration. BAT (Botulism Antitoxin Heptavalent (A, B, C, D, E, F, G) (Equine). Available athttps://www.fda.gov/vaccines-blood-biologics/approved-blood-products/bat-botulism-antitoxin-heptavalent-b-c-d-e-f-g-equine. Last accessed April 25, 2023.

181. Centers for Disease Control and Prevention. Antiviral Drug Resistance among Influenza Viruses. Available athttps://www.cdc.gov/flu/professionals/antivirals/antiviral-drug-resistance.htm. Last accessed April 25, 2023.

182. Koszalka P, Subbarao K, Baz M. Preclinical and clinical developments for combination treatment of influenza. PlOS Pathogens. 2022;18(5):e1010481.

183. Centers for Disease Control and Prevention. Reported Cases of Hantavirus Disease. Available athttps://www.cdc.gov/hantavirus/surveillance/index.html. Last accessed April 25, 2023.

184. Centers for Disease Control and Prevention. Hantavirus. Available athttps://www.cdc.gov/hantavirus. Last accessed April 25, 2023.

185. Centers for Disease Control and Prevention. Hantavirus. Multi-State Outbreak of Seoul Virus. Available athttps://www.cdc.gov/hantavirus/outbreaks/seoul-virus/index.html. Last accessed April 25, 2023.

186. Centers for Disease Control and Prevention. Hantavirus pulmonary syndrome—Vermont, 2000. MMWR. 2001;50(28):603-605.

187. Centers for Disease Control and Prevention. HPA Technical/Clinical Information. Available at https://www.cdc.gov/hantavirus/technical/hps/index.html. Last accessed April 25, 2023.

188. American Lung Association. Hantavirus Pulmonary Syndrome: Symptoms and Diagnosis. Available athttps://www.lung.org/lung-health-diseases/lung-disease-lookup/hantavirus-pulmonary-syndrome/symptoms-diagnosis. Last accessed April 25, 2023.

189. Centers for Disease Control and Prevention. Lymphocytic Choriomeningitis: Fact Sheet. Available athttps://www.cdc.gov/vhf/ lcm/pdf/factsheet.pdf. Last accessed April 25, 2023.

190. Centers for Disease Control and Prevention. Update: interim guidance for minimizing risk for human lymphocytic choriomeningitis virus infection associated with pet rodents. MMWR. 2005;54(Dispatch):1-3.

191. Fischer SA, Graham MB, Kuehnert MJ, et al. Transmission of lymphocytic choriomeningitis virus by organ transplantation. N Engl J Med. 2006;354(21):2235-2249.

192. Centers for Disease Control and Prevention. Variant Creutzfeldt-Jakob Disease. Available athttps://www.cdc.gov/prions/vcjd/index.html. Last accessed April 25, 2023.

193. U.S. Department of Health and Human Services. Food and Drug Administration. Center for Biologics Evaluation and Research. Recommendations to Reduce the Possible Risk of Transmission of Creutzfeldt-Jakob Disease and Variant Creutzfeldt-Jakob Disease by Blood and Blood Components: Guidance for Industry. Available at https://www.fda.gov/media/124156/download. Last accessed April 25, 2023.

194. Brown P, Will RG, Bradley R, Asher DM, Detwiler L. Bovine spongiform encephalopathy and variant Creutzfeldt-Jakob disease: background, evolution, and current concerns. Emerg Infect Dis. 2001;7(1):6-16.

195. Takemura K, Kahdre M, Joseph D, Yousef A, Sreevatsan S. An overview of transmissible spongiform encephalopathies. Anim Health Res Rev. 2004;5(2):103-124.

196. Centers for Disease Control and Prevention. BSE in North America. Available athttps://www.cdc.gov/prions/bse/bse-north-america.html. Last accessed April 25, 2023.

197. 197. George LW. Diseases of the nervous system. In: Smith BP (ed). Large Animal Internal Medicine. 5th ed. St. Louis, MO: Mosby-Year Book, Inc.; 2014.

198. Collinge J. Human prion diseases and bovine spongiform encephalopathy (BSE). Hum Mol Genet. 1997;6(10):1699-1705.

199. Wilesmith JW, Ryan JB, Atkinson MJ. Bovine spongiform encephalopathy: epidemiological studies on the origin. Veterinary Record. 1991;128:199-203.

200. Detwilder LA. Animal Transmissible Spongiform Encephalopathies (TSEs) and Their Impact on Animal and Human Health Worldwide. Yulee, FL: Proceedings of the American Association of Zoo Veterinarians; 1998.

201. Centers for Disease Control and Prevention. Investigation of progressive inflammatory neuropathy among swine slaughterhouse workers—Minnesota, 2007–2008. MMWR. 2008;57(5):1-3.

202. 202. Lachance DH. Outbreak of immune polyradiculoneuropathy in workers exposed to porcine neural tissue. Abstract LBS.001. Academy of Neurology 60th Annual Meeting. Presented April 16, 2008.

203. Thomas FP. Variant Cruetzfeldt-Jakob Disease and Bovine Spongiform Encephalopathy. Available athttps://emedicine.medscape.com/article/1169688-overview. Last accessed April 25, 2023.

204. Collie DA, Summers DM, Sellar RJ, et al. Diagnosing variant Creutzfeldt-Jakob disease with the pulvinar sign: MR imaging findings in 86 neuropathologically confirmed cases. Am J Neuroradiol. 2003;24(8):1560-1569.

205. Centers for Disease Control and Prevention. Variant Creutzfeldt-Jakob Disease: Risk for Travelers. Available athttps://www.cdc.gov/prions/vcjd/risk-travelers.html. Last accessed April 25, 2023.

206. Federal Register. Revised Preventive Measures to Reduce the Possible Risk of Transmission of Creutzfeldt-Jakob Disease (CJD) and Variant Creutzfeldt-Jakob Disease (vCJD) by Blood and Blood Products. Available at https://www.federalregister.gov/documents/2016/01/14/2016-00536/revised-preventive-measures-to-reduce-the-possible-risk-of-transmission-of-creutzfeldt-jakob-disease. Last accessed April 25, 2023.

207. Amaral L, Kristiansen JE. Phenothiazines: potential management of Creutzfeldt-Jakob disease and its variant. Int J Antimicrob Agents. 2001;18(5):411-417.

208. Centers for Disease Control and Prevention. Toxoplasmosis (Toxoplasma Infection). Available athttps://www.cdc.gov/parasites/toxoplasmosis. Last accessed April 25, 2023.

209. Foreyt WJ (ed). Veterinary Parasitology: Reference Manual. 5th ed. Ames, IA: Blackwell Publishing Professional; 2001.

210. Elmore SA, Jones JL, Conrad PA, Patton S, Lindsay DS, Dubey JP. Toxoplasma gondii: epidemiology, feline clinical aspects, and prevention. Trends Parasitol. 2010;26(4):190-196.

211. Kravetz JD, Federman DG. Cat-associated zoonoses. Arch Intern Med. 2002;162(17):1945-1952.

212. Dunn D, Wallon M, Peyron F, Petersen E, Peckham C, Gilbert R. Mother-to-child transmission of toxoplasmosis: risk estimates for clinical counselling. Lancet. 1999;353(9167):1829-1833.

213. Panel on Guidelines for the Prevention and Treatment of Opportunistic Infections in Adults and Adolescents with HIV. Guidelines for the Prevention and Treatment of Opportunistic Infections in Adults and Adolescents with HIV. National Institutes of Health, Centers for Disease Control and Prevention, HIV Medicine Association, and Infectious Diseases Society of America. Available at https://clinicalinfo.hiv.gov/sites/default/files/guidelines/documents/adult-adolescent-oi/guidelines-adult-adolescent-oi.pdf. Last accessed April 25, 2023.

214. Panel on Opportunistic Infections in Children with and Exposed to HIV. Guidelines for the Prevention and Treatment of Opportunistic Infections in Children with and Exposed to HIV. Department of Health and Human Services. Available at https://clinicalinfo.hiv.gov/sites/default/files/guidelines/documents/pediatric-oi/guidelines-pediatric-oi.pdf. Last accessed April 25, 2023.

215. Centers for Disease Control and Prevention. Parasites. Giardia. Available at https://www.cdc.gov/parasites/giardia. Last accessed April 25, 2023.

216. Adam RD. Biology of Giardia lamblia. Clin Microbiol Rev. 2001;14(3):447-475.

217. Buret AG. Mechanisms of epithelial dysfunction in giardiasis. Gut. 2007;56(3):316-317.

218. Nazer H. Giardiasis. Available athttps://emedicine.medscape.com/article/176718-overview. Last accessed April 25, 2023.

219. World Health Organization. Fact Sheet No. 94: Malaria. Available athttps://www.who.int/en/news-room/fact-sheets/detail/malaria. Last accessed April 25, 2023.

220. Centers for Disease Control and Prevention. Malaria's Impact Worldwide. Available athttps://www.cdc.gov/malaria/malaria_worldwide/impact.html. Last accessed April 25, 2023.

221. Centers for Disease Control and Prevention. Global Health: Malaria. Available athttps://www.cdc.gov/globalhealth/newsroom/topics/malaria. Last accessed April 25, 2023.

222. Centers for Disease Control and Prevention. Malaria Transmission in the United States. Available at https://www.cdc.gov/malaria/about/us_transmission.html. Last accessed April 25, 2023.

223. 223. Centers for Disease Control and Prevention. Malaria: Disease. Available athttps://www.cdc.gov/malaria/about/disease.html. Last accessed April 25, 2023.

224. World Health Organization. WHO Guidelines for Malaria. Available at https://www.mmv.org/sites/default/files/content/document/WHO-UCN-GMP-2023.01-eng.pdf. Last accessed April 25, 2023.

225. Centers for Disease Control and Prevention. Malaria Diagnosis (United States). Available athttps://www.cdc.gov/malaria/diagnosis_treatment/diagnosis.html. Last accessed April 25, 2023.

226. Rubio JM, Buhigas I, Subirats M, Baquero M, Puente S, Benito A. Limited level of accuracy provided by available rapid diagnosis tests for malaria enhances the need for PCR-based reference laboratories. J Clin Microbiology. 2001;39(7):2736-2737.

227. Centers for Disease Control and Prevention. Treatment of Malaria (Guidelines for Clinicians). Available at https://www.cdc.gov/malaria/diagnosis_treatment/clinicians1.html. Last accessed April 25, 2023.

228. Figtree M, Lee R, Bain L, et al. Plasmodium knowlesi in human, Indonesian Borneo. Emerg Infect Dis. 2010;16(4):672-674.

229. Lo Re V III, Gluckman SJ. Prevention of malaria in travelers. Am Fam Phys. 2003;68(3):509-514.

230. 230. Cennimo DJ. Anthrax. Available athttps://emedicine.medscape.com/article/212127-overview. Last accessed April 25, 2023.

231. Inglesby TV, O'Toole T, Henderson DA, et al. Anthrax as a biological weapon, 2002: updated recommendations for management. JAMA. 2002;287(17):2236-2252.

232. Use of anthrax vaccine in the United States: Recommendations of the Advisory Committee on Immunization Practices, 2019. MMWR. 2019;68(4):1-14.

233. Heninger SJ, Anderson CA, Beltz G, Onderdonk AB. Decontamination o. Bacillus anthracis spores: evaluation of various disinfectants. Appl Biosaf. 2009;14(1):7-10.

234. Centers for Disease Control and Prevention. Anthrax. Available at https://www.cdc.gov/anthrax/basics/types/index.html. Last accessed April 25, 2023.

235. Shadomy SV, Traxler RM, Marston CK. Infectious diseases related to travel: anthrax. In: CDC's Health Information for International Travel: 2016 (Yellow Book). New York, NY: Oxford University Press; 2015.

236. Hendricks KA, Wright ME, Shadomy SV, et al. Centers for Disease Control and Prevention expert panel meetings on prevention and treatment of anthrax in adults. Emerg Infect Dis. 2014;20(2).

237. Withers MR (ed). Medical Management of Biological Casualties Handbook. 8th ed. Fort Detrick, MD: US Army Medical Research Institute of Infectious Diseases; 2014.

238. Bower WA, Schiffer J, Atmar RL, et al. Use of anthrax vaccine in the United States: recommendations of the Advisory Committee on Immunization Practices, 2019. MMWR. 2019;68(4):1-14.

239. Jang KH, Nam S-J, Locke JB, et al. Anthracimycin, a potent anthrax antibiotic from a marine-derived actinomycete. Angew Chem Int Ed Engl. 2013;52(30):7822-7824.

240. Stern EJ, Uhde KB, Shadomy SV, Messonnier N. Conference report on public health and clinical guidelines for anthrax. Emerg Infect Dis. 2008;14(4).

241. U.S. Food and Drug Administration. [Archived Content]. FDA Approves Treatment for Inhalation Anthrax. Available athttps://wayback.archive-it.org/7993/20170405005211/https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm439752.htm. Last accessed April 25, 2023.

242. U.S. Food and Drug Administration.Vibrio vulnificus Health Education Kit Fact Sheet. Available at https://www.fda.gov/food/health-educators/vibrio-vulnificus-health-education-kit-fact-sheet. Last accessed April 25, 2023.

243. World Health Organization. Cholera. Available athttps://www.who.int/health-topics/cholera. Last accessed April 25, 2023.

244. Centers for Disease Control and Prevention. Vibrio cholerae Infection: Treatment. Available athttps://www.cdc.gov/cholera/treatment/index.html. Last accessed April 25, 2023.

245. U.S. Food and Drug Administration. FDA Approves Vaccine to Prevent Cholera for Travelers. Available athttps://www.fda.gov/news-events/press-announcements/fda-approves-vaccine-prevent-cholera-travelers. Last accessed April 25, 2023.

246. Bennett WN. Botulism. Available athttps://emedicine.medscape.com/article/213311-overview. Last accessed April 25, 2023.

247. World Health Organization. Botulism. Available at https://www.who.int/news-room/fact-sheets/detail/botulism#. Last accessed April 25, 2023.

248. McCarty CL, Angelo K, Beer KD, et al. Large outbreak of botulism associated with a church potluck meal—Ohio, 2015. MMWR. 2015;64(29):802-803.

249. Shapiro RL, Hatheway C, Becher J, Swerdlow DL. Botulism surveillance and emergency response: a public health strategy for a global challenge. JAMA. 1997;278(5):433-435.

250. Centers for Disease Control and Prevention. Botulism. Available athttps://www.cdc.gov/botulism. Last accessed April 25, 2023.

251. Centers for Disease Control and Prevention. Investigational heptavalent botulinum antitoxin (HBAT) to replace licensed botulinum antitoxin AB and investigational botulinum antitoxin E. MMWR. 2010;59(10):299.

252. California Department of Public Health. Infant Botulism Treatment and Prevention Program. Available athttps://www.cdph.ca.gov/Programs/CID/DCDC/Pages/IBTPP_International_Inquiries.aspx. Last accessed April 25, 2023.

253. Centers for Disease Control and Prevention. Botulism in the United States, 1899–1996: Handbook for Epidemiologists, Clinicians, and Laboratory Workers. Available athttps://www.cdc.gov/botulism/pdf/bot-manual.pdf. Last accessed April 25, 2023.

254. World Health Organization. Salmonella(Non-Typhoidal). Available at https://www.who.int/en/news-room/fact-sheets/detail/salmonella-(non-typhoidal). Last accessed April 25, 2023.

255. 255. Centers for Disease Control and Prevention. Salmonellosis: Information for Healthcare Professionals and Laboratories. Available athttps://www.cdc.gov/salmonella/general/technical.html. Last accessed April 25, 2023.

256. Centers for Disease Control and Prevention. Healthy Pets, Healthy People: Salmonella Infection. Available athttps://www.cdc.gov/healthypets/diseases/salmonella.html. Last accessed April 25, 2023.

257. Centers for Disease Control and Prevention. Salmonella: Questions and Answers. Available athttps://www.cdc.gov/salmonella/general/index.html. Last accessed April 25, 2023.

258. Onwuezobe IA, Oshun PO, Odigwe CC. Antimicrobials for treating symptomatic non-typhoidal Salmonella infection. Cochrane Database Syst Rev. 2012;11:CD001167.

259. Cody SH, Abbott SL, Marfin AA, et al. Two outbreaks of multidrug-resistantSalmonella serotype typhimurium DT104 infections linked to raw-milk cheese in Northern California. JAMA. 1999;281(19):1805-1810.

260. Bouza E, Sánchez-Carrillo C, Hernangómez S, González MJ. Laboratory-acquired brucellosis: a Spanish national survey. J Hosp Infect. Sep 2005;61(1):80-83.

261. 261. U.S. Department of Agriculture. Brucellosis and Yellowstone Bison. Available athttps://www.aphis.usda.gov/animal_health/animal_dis_spec/cattle/downloads/cattle-bison.pdf. Last accessed April 25, 2023.

262. Gerberding JL, Romero JM, Ferraro MJ. Case records of the Massachusetts General Hospital. Case 34-2008: a 58-year-old woman with neck pain and fever. N Engl J Med. 2008;359(18):1942-1949.

263. Centers for Disease Control and Prevention. Brucellosis. Available athttps://www.cdc.gov/brucellosis. Last accessed April 25, 2023.

264. Centers for Disease Control and Prevention. National Center for Emerging and Zoonotic Infectious Diseases. Brucellosis Reference Guide: Exposures, Testing, and Prevention. Available at https://www.cdc.gov/brucellosis/pdf/brucellosi-reference-guide.pdf. Last accessed April 25, 2023.

265. Yousefi-Nooraie R, Mortaz-Hejri S, Mehrani M, Sadeghipour P. Antibiotics for treating human brucellosis. Cochrane Database Syst Rev. 2012;10:CD007179.

266. Northrop-Clewes CA, Shaw C. Parasites. Br Med Bull. 2000;56(1):193-208.

267. Centers for Disease Control and Prevention. Laboratory Identification of Parasitic Diseases of Public Health Concern: Trichinellosis. Available athttps://www.cdc.gov/dpdx/trichinellosis/index.html. Last accessed April 25, 2023.

268. 268. de Silva N, Guyatt H, Bundy D. Anthelmintics: a comparative review of their clinical pharmacology. Drugs. 1997;53(5):769-788.

269. Centers for Disease Control and Prevention. Dipylidium Infection (Also Known As Dog and Cat Flea Tapeworm). Available athttps://www.cdc.gov/parasites/dipylidium. Last accessed April 25, 2023.

270. Minnaganti VR. Dipylidiasis. Available at https://emedicine.medscape.com/article/216184-overview. Last accessed April 25, 2023.

271. Abba K, Ramaratnam S, Ranganathan LN. Anthelmintics for people with neurocysticercosis. Cochrane Database Syst Rev. 2010;(1):CD000215.

272. Centers for Disease Control and Prevention. Parasites: Anisakiasis. Available at https://www.cdc.gov/parasites/anisakiasis/index.html. Last accessed April 25, 2023.

273. Weir E. Sushi, nemotodes, and allergies. CMAJ. 2005;172(3):329.

274. Kita R, Hashida H, Uryuhara K, Kaihara S. Hepatic anisakiasis mimicking metastatic liver tumour. Int J Surg Case Rep. 2019;60:209-212.

275. John, DT, Petri WA. The intestinal nematodes. In: Markell and Voge's Medical Parasitology. 9th ed. St. Louis, MO: Saunders; 2013: 239-273.

276. Hwa-Froelich DA, Westby CE. Considerations when working with interpreters. Commun Disord Q. 2003;24(2):78-85.

  • Back to Course Home
  • Participation Instructions
    • Review the course material online or in print.
    • Complete the course evaluation.
    • Review your Transcript to view and print your Certificate of Completion. Your date of completion will be the date (Pacific Time) the course was electronically submitted for credit, with no exceptions. Partial credit is not available.